Prostate Cancer

Cytogen presents promising data from combination trials with QUADRAMET and Docetaxel

Published in Cancer Weekly, July 4th, 2006

Cytogen Corporation (CYTO) announced the presentation of data from two Phase II clinical trials of QUADRAMET (samarium Sm-153 lexidronam injection) in combination with docetaxel (Taxotere, Aventis Pharmaceuticals, a member of the Sanofi-Aventis Group) in patients with progressive hormone refractory prostate cancer and bone metastases.

Findings from the investigator-sponsored studies indicate that the combination regimens, known as TAXSAM, are well tolerated, provide pain palliation, and demonstrate promising rates of clinical and biochemical responses. Results were presented at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Atlanta,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-07-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry